オプションチェーンは、Teva Pharmaceutical Indusの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Teva Pharmaceutical Indusの市場センチメントを評価します。.

Teva Pharmaceutical Indus (NYSE:TEVA) 株価情報, オプションチェーン

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARMA IND ADR REP 1 ORD

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $4.12 billion</a>.
Revenues increased 13% year-over-year and 15% on constant currency. This was mainly due to higher revenues from generic products in all segments (i.e., Austedo in the U.S. segment), and the sale of product rights in Europe and <a href="https://www.benzinga.com/pressreleases/24/11/g41769774/teva-announces-strong-financial-results-for-the-third-quarter-of-2024-led-by-generics-performance-" target="_blank" rel="noreferrer noopener">International Markets segments</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384005/amicus-therapeutics-settles-patent-lawsuit-teva-pharmaceuticals-over-generic-version-of-its-rare-" rel="noreferrer noopener">Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug</a>
Generics business grows across all regions — increased by 30% in the U.S., 8% in Europe, and 13% in International Markets, in local currency terms compared to Q3 2023.
Generic products revenues in the U.S. segment (including biosimilars) were $1.09 billion, up 30% year over year, the majority of which was driven by higher revenues from lenalidomide capsules (the generic version of Bristol Myers Squibb &amp; Co&#8217;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) Revlimid), and the remaining, primarily by the launch of liraglutide injection 1.8mg — an authorized generic of Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Victoza — and higher revenues from epinephrine injectable solution (the generic equivalent of EpiPen and EpiPen Jr).
<ul>
<li>Austedo U.S. revenues increased 28% to $435 million. Ajovy's global revenues increased by 21% to $137 million.</li>
<li>Uzedy&#8217;s U.S. revenues of $35 million.</li>
<li>Teva says its intention to divest Teva API is on track, targeting completion in the first half of 2025.</li>
<li>Adjusted EPS of 69 cents, higher than 60 cents a year ago, beating the consensus of 66 cents.</li>
<li>Adjusted gross profit margin&nbsp;was 53.7% in the third quarter of 2024, compared to 53.5% in the third quarter of 2023.</li>
<li>Adjusted operating margin reached 28%, down from 26.5% a year ago.</li>
<li>Adjusted EBITDA&nbsp;was $1.34 billion in the third quarter of 2024, an increase of 17%.</li>
</ul>
Outlook:&nbsp;Teva expects fiscal year 2024 revenues of $16.1 billion-$16.5 billion versus <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40071226/teva-beats-q2-estimates-raises-annual-outlook-on-strong-generic-austedo-sales" rel="noreferrer noopener">prior guidance of</a> $16.0 billion—$16.4 billion and consensus of $16.256 billion.
The generic pharma player expects 2024 adjusted EPS of $2.40-$2.50 versus prior guidance of $2.30-$2.50 and consensus of $2.45.
The company raised 2024 Uzedy sales guidance from around $80 million to approximately $100 million.
Price Action: Teva stock is up 1.76% at $19.10 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41773974/energy-drink-maker-celsius-misses-on-q3-earnings-as-supply-chain-optimization-weighs-on-margins-det" target="_blank" rel="noreferrer noopener">Energy Drink Maker Celsius Misses On Q3 Earnings As Supply Chain Optimization Weighs On Margins: Details</a></li>
</ul>

Biotech

Earnings

Large Cap

News

Guidance

Health Care

General

TEVA

Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast

Teva Pharmaceutical CEO Francis Says Expects Generics Prices To Be Pushed Down In 2025

Teva shares are trading higher after the company reported better-than-expected Q3 earnings and raised its guidance.

Teva Forecasts 2024 Revenues Of $16.1B-$16.5B Versus Prior Guidance Of $16.0B-$16.4B And Consensus Of $16.256B

Outlook for 2024 Non-GAAP Results
<figure class="table"> 
<table>
<tbody>
<tr>
<td>$ billions, except EPS or as noted</td>
<td>November 2024 Outlook</td>
<td>July 2024 Outlook</td>
<td>February 2024 Outlook</td>
</tr>
<tr>
<td>Revenues&#x2A;</td>
<td>$16.1 - $16.5</td>
<td>$16.0 - $16.4</td>
<td>$15.7 - $16.3</td>
</tr>
<tr>
<td>AUSTEDO ($m)&#x2A;</td>
<td>~1,600</td>
<td>~1,600</td>
<td>~1,500</td>
</tr>
<tr>
<td>AJOVY ($m)&#x2A;</td>
<td>~500</td>
<td>~500</td>
<td>~500</td>
</tr>
<tr>
<td>UZEDY ($m)&#x2A;</td>
<td>~100</td>
<td>~80</td>
<td>~80</td>
</tr>
<tr>
<td>COPAXONE ($m)&#x2A;</td>
<td>~500</td>
<td>~450</td>
<td>~400</td>
</tr>
<tr>
<td>Operating Income</td>
<td>4.2 - 4.5</td>
<td>4.1 - 4.5</td>
<td>4.0 - 4.5</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>4.7 - 5.0</td>
<td>4.6 - 5.0</td>
<td>4.5 - 5.0</td>
</tr>
<tr>
<td>Finance Expenses ($m)</td>
<td>~1,000</td>
<td>~1,000</td>
<td>~1,000</td>
</tr>
<tr>
<td>Tax Rate</td>
<td>14% - 17%</td>
<td>14% - 17%</td>
<td>14% - 17%</td>
</tr>
<tr>
<td>Diluted EPS ($)</td>
<td>2.40 - 2.50</td>
<td>2.30 - 2.50</td>
<td>2.20 - 2.50</td>
</tr>
<tr>
<td>Free Cash Flow&#x2A;&#x2A;</td>
<td>1.7 - 2.0</td>
<td>1.7 - 2.0</td>
<td>1.7 - 2.0</td>
</tr>
<tr>
<td>CAPEX&#x2A;</td>
<td>~0.5</td>
<td>~0.5</td>
<td>~0.5</td>
</tr>
<tr>
<td>Foreign Exchange</td>
<td colspan="2">Volatile swings in FX can negatively impact revenue and income</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Teva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.66 by 4.55 percent. The company reported quarterly sales of $4.33 billion which beat the analyst consensus estimate of $4.12 billion by 5.16 percent. This is a 12.52 percent increase over sales of $3.85 billion the same period last year.

Teva Pharmaceutical Indus Q3 2024 Adj EPS $0.69 Beats $0.66 Estimate, Sales $4.33B Beat $4.12B Estimate

<ul>
<li>IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person's underlying mental health condition</li>
<li>Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)</li>
<li>Teva continues to further innovations in mental health and progress real-world data to improve treatment optimization</li>
</ul>
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO&#xAE; XR&#xAE; (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Teva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received TD Diagnoses Compared To Those With Mood Disorders (50%)

<ul>
<li>Teva's presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience</li>
<li>Data show TEV-'749 drug delivery technology resulted in no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date</li>
<li>Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable reveal high adherence rates and utilization in adults with schizophrenia who have barriers to treatment &nbsp;</li>
</ul>
TEL AVIV, Israel &amp; PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.
Schizophrenia is a complex medical condition which can severely impact quality of life and social functioning. These new results demonstrate the potential benefits TEV-'749 may have for patients utilizing this form of a long-acting injectable (LAI) treatment option including improving quality life and social functioning.1

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements In Social Functioning And Quality Of Life In Adults Receiving TEV-'749, A Subcutaneous Long-Acting Injectable As Well As Results Of Real-World Analyses Of UZEDY; Analysis Of UZEDY Highlights High Adherence And Usage Among Patients With Treatment Barriers

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has outperformed the market over the past 5 years by 2.31% on an annualized basis producing an average annual return of 15.92%. Currently, Teva Pharmaceutical Indus has a market capitalization of $20.87 billion. 
Buying $1000 In TEVA: If an investor had bought $1000 of TEVA stock 5 years ago, it would be worth $2,205.99 today based on a price of $18.42 for TEVA at the time of writing.
<h3>Teva Pharmaceutical Indus's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730219415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today

In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.75, a high estimate of $26.00, and a low estimate of $18.00. Marking an increase of 9.64%, the current average surpasses the previous average price target of $20.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1729692010_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Teva Pharmaceutical Indus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Teva Pharmaceutical Indus's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>Discovering Teva Pharmaceutical Indus: A Closer Look</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Breaking Down Teva Pharmaceutical Indus's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Teva Pharmaceutical Indus's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.4% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -20.32%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Teva Pharmaceutical Indus's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -12.41%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio is below the industry average at 2.98, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Overweight and raises the price target from $22 to $25.

Price Target

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $25

This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara&reg;&nbsp;(ustekinumab) in the U.S. at launch, which is expected in the&nbsp;first quarter&nbsp;of 2025.

ALVO

Alvotech, Teva Reports FDA Approval For SELARSDI (Ustekinumab-aekn) In New Presentation, 130 Mg/26 Ml (5 Mg/Ml) Solution In Single-dose Vial For Intravenous Infusion

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Neutral and raises the price target from $16 to $18.

JP Morgan Maintains Neutral on Teva Pharmaceutical Indus, Raises Price Target to $18

On Thursday, Amicus Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
The <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41376664/amicus-therapeutics-announces-settlement-of-galafold-migalastat-patent-litigation-with-teva" rel="noreferrer noopener">agreement resolves</a> the patent litigation brought by Amicus in response to Teva&#8217;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Galafold (migalastat) 123mg capsules before the expiration of the applicable patents.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41295664/teva-pays-450m-to-resolve-alleged-kickback-price-fixing-schemes" rel="noreferrer noopener">Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes</a>.
Galafold is a medication for Fabry disease, a rare genetic disorder caused by the buildup of a type of fat called globotriaosylceramide in the body&#8217;s cells.
Under the terms of the Agreement, Amicus will grant Teva a license to market its generic version of Galafold&nbsp;in the&nbsp;United States&nbsp;beginning on January 30, 2037, if approved by the FDA and unless certain limited circumstances customarily included in these types of agreements occur.
The parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding Galafold patents pending in the U.S. District Court for the District of Delaware.
The litigation will continue against Aurobindo&nbsp;as the remaining active party, and the litigation stay remains in place for Lupin.
Price Action: TEVA stock is up 0.47% at $18.11, and FOLD stock is up 12.4% at $11.81 at last check Thursday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41381891/commercial-metals-q4-eps-beats-by-a-whisker-but-outlook-signals-tough-start-to-2025" target="_blank" rel="noreferrer noopener">Commercial Metals Q4 EPS Beats By A Whisker, But Outlook Signals Tough Start To 2025</a>.</li>
</ul>

Equities

Legal

Movers

FOLD

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

This Agreement resolves the patent litigation brought by Amicus in response to Teva&#39;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of GALAFOLD&nbsp;(migalastat) 123mg capsules prior to expiration of the applicable patents.
Pursuant to the terms of the Agreement, Amicus will grant Teva a license to market its generic version of GALAFOLD&nbsp;in the&nbsp;United States&nbsp;beginning on January 30, 2037, if approved by the U.S. Food and Drug Administration (FDA) and unless certain limited circumstances customarily included in these types of agreements occur.
In accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding GALAFOLD&nbsp;patents pending in the U.S. District Court for the District of Delaware. The litigation will continue against Aurobindo1&nbsp;as the remaining active party and the litigation stay remains in place for Lupin.

Amicus Therapeutics Enters License Agreement With Teva, Resolving Galafold Patent Litigation; No Terms Disclosed

Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has agreed to a $450 million settlement with the U.S. government to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40801368/teva-announces-80m-settlement-to-baltimore-city-continues-opioid-litigation-against-other-compani" rel="noreferrer noopener">False Claims Act (FCA)</a>.
The settlement stems from claims that Teva engaged in two unlawful kickback schemes, impacting Medicare and the pricing of essential drugs.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40957505/eli-lilly-fights-183m-medicaid-fraud-judgment-cites-reasonable-interpretation-of-medicaid-rules" rel="noreferrer noopener">Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules</a>.
This resolution includes $225 million in criminal penalties that Teva USA previously paid as part of a deferred prosecution agreement with the Department of Justice.
The first kickback <a target="_blank" href="https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback" rel="noreferrer noopener">scheme</a> involved allegations that Teva violated the AKS by covering Medicare patients&#8217; copays for the multiple sclerosis drug Copaxone between 2006 and 2017.
During this period, Teva is accused of coordinating with third parties, including a specialty pharmacy and two supposedly independent copay assistance foundations, to direct donations to cover patients&#8217; Copaxone copays.
According to federal prosecutors, these actions were prohibited by the AKS and caused false claims to be submitted to Medicare as Teva simultaneously raised the drug&#8217;s price.
The second scheme alleges that Teva USA conspired with other generic drug manufacturers to fix the prices of pravastatin, a cholesterol-lowering drug, clotrimazole, and tobramycin, two additional generics.
The Justice Department had previously secured a deferred prosecution agreement with Teva USA, where the company admitted to participating in price-fixing activities.
The settlement is part of a broader initiative against price-fixing and kickbacks in the pharmaceutical industry.
According to Joshua S. Levy, Acting U.S. Attorney for the District of Massachusetts, Teva&#8217;s manipulation of the charitable foundation process violated the AKS and undermined Medicare&#8217;s copay system. His office has played a central role in these enforcement actions, returning over $1 billion to Medicare since 2017.
This settlement is the largest among a series of cases targeting pharmaceutical companies that unlawfully paid patient copays through third-party foundations.
The Justice Department has secured over $1 billion from these companies and reached settlements with four foundations and a specialty pharmacy.
Price Action: TEVA stock is down 0.34% at $17.35 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41289783/jpmorgan-chase-q3-earnings-investment-banking-revenue-soars-29-raises-fy24-net-interest-income-outl" target="_blank" rel="noreferrer noopener">JPMorgan Chase Q3 Earnings: Investment Banking Revenue Soars 29%, Largest Bank Raises Net Interest Income Outlook</a>.</li>
</ul>

Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes

<a href="https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback" title="https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback">https://www.justice.gov/opa/pr/drug-maker-teva-pharmaceuticals-agrees-pay-450m-false-claims-act-settlement-resolve-kickback</a>

'Drug Maker Teva Pharmaceuticals Agrees to Pay $450M in False Claims Act Settlement to Resolve Kickback Allegations Relating to Copayments and Price Fixing' - DOJ

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has outperformed the market over the past 5 years by 6.31% on an annualized basis producing an average annual return of 20.33%. Currently, Teva Pharmaceutical Indus has a market capitalization of $19.92 billion. 
Buying $100 In TEVA: If an investor had bought $100 of TEVA stock 5 years ago, it would be worth $261.22 today based on a price of $17.58 for TEVA at the time of writing.
<h3>Teva Pharmaceutical Indus's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728572432_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today

The FDA&#39;s anticipated decision and EMA&#39;s expected opinion are anticipated in the second half of 2025.

Teva Says FDA Has Accepted, And The European Medicines Agency Has Validated, Applications For TVB-009P, A Biosimilar Candidate To Prolia

Macro Notification

DARE

PGNY

PRGO

US State Of Georgia's Supreme Court Reinstates Abortion Ban That Was Blocked By Lower Court

Earnings week ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and more

Teva Pharmaceutical Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price targe...

Barclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

Teva gains after raising outlook for second time this year

Sees FY24 capital expenditures $500M. Sees FY24 free cash flow $1.7B-$2B. Says on track for FY27 targets. Guidance taken from Q3 earnings conferenc...

Teva sees FY24 adjusted EBITDA $4.7B-$5B

Teva Pharmaceutical Industries Limited 2024 Q3 - Results - Earnings Call Presentation

Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Trump Media (DJT) jumps after Donald T...

Trump Media, broader market surge after Trump wins election: Morning Buzz

SA Asks: How will the U.S. election results impact healthcare stocks?

AAPL

ABBV

ABNB

ABUS

ADRNY

AFRM

AMGN

ANET

ATHM

AUDC

AVDX

BLNK

BMWYY

BNTX

BYND

CBOE

CELH

CLBT

CNDT

CRSP

CTKB

CTVA

DDOG

DKNG

EHTH

ENOV

EXAS

FANG

FHLC

FIVE

GILD

HENKY

HNDAF

HNHAF

HNHPF

ILMN

IONS

IRBT

LCID

LNTH

LUMN

LYFT

MAIN

MARA

MCFT

MKTX

MOGO

MRNA

NEON

NTDOF

NTDOY

NVAX

NXPI

OESX

OPEN

PACS

PARA

PERI

PFGC

PINS

PLNT

PLTR

QCOM

RIVN

RPRX

RVLV

SEDG

SMCI

SNDR

SNOW

SONY

SPCE

STLA

STWD

TCPC

TEVJF

TNGX

TRMB

TTWO

TWLO

UPST

URGN

VONOY

VRNOF

VRTX

VTRS

WYNN

Press Releases

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Teva Statement on European Commission Decision; Company to Appeal

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Comments

Teva Pharmaceutical Indus

Teva Pharmaceutical Indus (TEVA) オプション

Teva Pharmaceutical Indus (NYSE:TEVA) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル